Spartalizumab
Showing 1 - 25 of 54
Oesophageal Adenocarcinoma, Gastric Adenocarcinoma Trial in France (Capmatinib, Spartalizumab)
Suspended
- Oesophageal Adenocarcinoma
- Gastric Adenocarcinoma
- Capmatinib
- Spartalizumab
-
Besançon, France
- +6 more
Feb 1, 2023
Triple-negative Breast Cancer Trial in Worldwide (LAG525, Spartalizumab, Carboplatin)
Carcinoma, Renal Cell Trial in New York (Spartalizumab, Canakinumab)
Recruiting
- Carcinoma, Renal Cell
- Spartalizumab
- Canakinumab
-
New York, New YorkColumbia University Medical Center
May 6, 2022
Head and Neck Squamous Cell Carcinoma Trial in Taipei (Ribociclib, Spartalizumab)
Active, not recruiting
- Head and Neck Squamous Cell Carcinoma
- Ribociclib
- Spartalizumab
-
Taipei, TaiwanNational Taiwan University Hospital
Apr 19, 2022
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID
Active, not recruiting
- Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
- +2 more
- Dabrafenib
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Aug 9, 2022
Metastatic Pancreatic Ductal Adenocarcinoma Trial in Boston, New York (Canakinumab injection; spartalizumab, nab-paclitaxel,
Active, not recruiting
- Metastatic Pancreatic Ductal Adenocarcinoma
- Canakinumab injection; spartalizumab, nab-paclitaxel, gemcitabine
-
Boston, Massachusetts
- +1 more
Apr 5, 2022
Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 Trial in Atlanta (Siltuximab, Spartalizumab)
Recruiting
- Metastatic Pancreatic Adenocarcinoma
- Stage IV Pancreatic Cancer AJCC v8
- Siltuximab
- Spartalizumab
-
Atlanta, Georgia
- +2 more
Feb 1, 2022
Refractory or Recurrent Solid Tumor Trial in France (Spartalizumab in Pediatric cohort, Low-dose Pazopanib in Pediatric Cohort,
Not yet recruiting
- Refractory or Recurrent Solid Tumor
- Spartalizumab in Pediatric cohort
- +3 more
-
Angers, France
- +8 more
Mar 9, 2022
MSI-H Colorectal Cancer, Melanoma, Anal Carcinoma Trial in Spain (Spartalizumab)
Active, not recruiting
- MSI-H Colorectal Cancer
- +30 more
- Spartalizumab
-
Badalona, Barcelona, Spain
- +9 more
Oct 24, 2022
Squamous Cell Anal Carcinoma, Metastatic Squamous Cell Carcinoma Trial in Besançon, Lyon, Montbeliard (Sample collection)
Recruiting
- Squamous Cell Anal Carcinoma
- Metastatic Squamous Cell Carcinoma
- Sample collection
-
Besançon, France
- +2 more
Mar 10, 2022
Non-small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, Esophageal SCC Trial in Worldwide (TNO155, Spartalizumab,
Recruiting
- Non-small Cell Lung Carcinoma
- +4 more
- TNO155
- +2 more
-
Boston, Massachusetts
- +8 more
Mar 18, 2022
NSCLC Trial in Worldwide (Capmatinib, Spartalizumab, Docetaxel)
Completed
- Carcinoma, Non-Small-Cell Lung
- Capmatinib
- +2 more
-
Fayetteville, Arkansas
- +7 more
Jan 21, 2022
MDS, Leukemia, Myelomonocytic, Chronic Trial (decitabine, Spartalizumab, Sabatolimab)
Not yet recruiting
- Myelodysplastic Syndromes
- Leukemia, Myelomonocytic, Chronic
- decitabine
- +5 more
- (no location specified)
Aug 5, 2022
Gastric Cancer by AJCC V8 Stage, Resectable Carcinoma Trial in Caen (perioperative treatment)
Recruiting
- Gastric Cancer by AJCC V8 Stage
- Resectable Carcinoma
- perioperative treatment
-
Caen, FranceCentre François Baclesse
Jun 28, 2021
BRAF V600 Colorectal Cancer Trial in Worldwide (Dabrafenib, LTT462, Trametinib)
Recruiting
- BRAF V600 Colorectal Cancer
- Dabrafenib
- +6 more
-
Los Angeles, California
- +17 more
Jun 7, 2022
Nasopharyngeal Carcinoma Trial in Worldwide (Spartalizumab, Investigator choice of chemo)
Completed
- Nasopharyngeal Carcinoma
- Spartalizumab
- Investigator choice of chemotherapy
-
Marietta, Georgia
- +17 more
Jan 17, 2022
Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma Trial in United States (Gemcitabine combined with
Recruiting
- Metastatic Pancreatic Cancer
- Metastatic Pancreatic Adenocarcinoma
- Gemcitabine combined with nab-paclitaxel
- +4 more
-
La Jolla, California
- +20 more
Aug 18, 2022
Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma Trial in Worldwide (PDR001, ACZ885, CJM112)
Completed
- Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma
- PDR001
- +4 more
-
Baltimore, Maryland
- +22 more
Mar 15, 2022
Metastatic Colorectal Cancer Trial in Worldwide (spartalizumab (PDR001), regorafenib)
Completed
- Metastatic Colorectal Cancer
- spartalizumab (PDR001)
- regorafenib
-
St Leonards, New South Wales, Australia
- +10 more
Dec 9, 2020